The use of memantine and brimonidine to attenuate vitreoretinal vascular endothelial growth factor (VEGF) protein levels in animals

Details for Australian Patent Application No. 2007207631 (hide)

Owner Allergan, Inc.

Inventors Gil, Daniel W.; Kusari, Jyotimoy X.

Agent Davies Collison Cave

Pub. Number AU-A-2007207631

PCT Pub. Number WO2007/084473

Priority 60/759,905 17.01.06 US

Filing date 16 January 2007

Wipo publication date 26 July 2007

International Classifications

A61P 27/02 (2006.01) Drugs for disorders of the senses

A61K 31/13 (2006.01) - Amines, e.g. amantadine

A61K 31/4168 (2006.01)

A61K 31/498 (2006.01) - Pyrazines or piperazines ortho- or peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine

Event Publications

31 July 2008 PCT application entered the National Phase

  PCT publication WO2007/084473 Priority application(s): WO2007/084473

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2007207632-Wire guide having distal coupling tip

2007207629-Selective catalysts for naphtha hydrodesulfurization